The past 20 years have seen dramatic changes in the delivery of radiation therapy, but the
impact of radiobiology on the clinic has been far less substantial. A major consideration in …

Highlights•CD8+ T cells and NK cells are both cytotoxic cells with engineering potential.•NK
cells are comparable to CD8+ T cells but far less understood.•Cancer immunotherapies …

Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics …

Immunotherapy provides the best approach to reduce the high mortality of metastatic breast
cancer (BC). We demonstrate a chemo-immunotherapy approach, which utilizes a liposomal …

Improved understanding of molecular drivers of carcinogenesis has led to significant
progress in the management of lung cancer. Patients with non-small-cell lung cancer …

Abstract Pembrolizumab [Keytruda®(US)], a humanized monoclonal antibody against the
programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the …

Tumor‐associated macrophages (TAMs) are essential components of the tumor
microenvironment involved in the progression and metastasis of cancer. They are intimately …

Lung cancer remains one of the most common malignancies in the world. Nowadays, the
most common lung cancer is non-small cell lung cancer (NSCLC), namely …

Abstract The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial
designed to advance the efficient development of targeted therapies for squamous cell …

Inhibitory receptors expressed on T cells control immune responses while limiting
autoimmunity. However, tumors can hijack these “checkpoints” for protection from immune …